Monthly Archives: August 2017

Take a Virtual Walk with Porfirio Sanchez Galindo

Who is Porfirio Sanchez Galindo?

Porfirio Sanchez Galindo is native to Mexico, and the International Vice President of Grupo Editorial Televisa.

What is Grupo Editorial Televisa?

Grupo Editorial Televisa is the editorial division of Grupo Televisa, which is Latin America’s largest multimedia mass media company. In addition, it is said to be the largest multimedia mass media company throughout the entire Spanish speaking world.

Sanchez Galindo spent over 8 years with Grupo Televisa as the director of Special Projects since 2006, then received a promotion as the International Vice President for Grupo Editorial Televisa.

Porfirio Sanchez Galindo worked within the Mexican government as a career diplomat. His extensive knowledge on the operations of the economic environment, as well as impacts from policies of the government has led him to this deserved promotion.

It is vital for Televisa that they retain someone like Sanchez Galindo due to his detailed knowledge as listed above. He also is well versed on both global and local economic environments and how they operate. Galindo is able to identify opportunities, as well as the antithesis, that play key roles in Televisa’s movement to bring him on.

Porfirio Sanchez Galindo’s Education & Career Background

Galindo has an extensive educational background with solid academics and many years of experience spent as a career diplomat. When Galindo joined the Mexican government in 2000, his skills were put to the test, where he also improved on areas of economic issues. He serviced as Chief of Staff in the Finance Ministry, formerly heading as Minister. Although no experience as a career diplomat at this time, Galindo more than excelled in his new position as the Minister’s Economic Advisor. He would be in this role until 2006. Shortly thereafter, he was hired by Televisa who had him in place to serve as Chief Economist of the company.

Porfiro Sánchez Galindo is certainly a man whom has achieved numerous successes, positive innovations and much more, bringing all to the world of editorial journalism. Because of him, we can be grateful for the amazing realm of Grupo Editorial Televisa.

One of a kind Oncologist newsletter

Oncotarget is a company based on oncological research. Since, its formation, the company has been working to bring innovations in the field of oncology to introduce better treatments and drugs for cancer patients. Oncotarget is basically a newsletter that works on peer to peer review. People from anywhere can share their research work on oncology in this newsletter and can share their knowledge with others. It provides doctors from all over the world a platform to share their work. It is a way of connecting doctors who can interact with each other and can get benefit from each other’s research work. In this way, they make sure they can help the cancer patients in every possible way.

The first newsletter was published by Oncotarget in 2010. Since then it has gained a lot of attention and praise among its readers. Its huge success is due to the fact that it is for doctors and by doctors. That is why it is greatly appreciated by doctors specifically oncologists. These doctors are highly experienced treating patients for many years. They are also aware of the new treatments and innovations in the technology for treatment. Mr. Andrei Gudkov and Mikhail Blagosklonny are its owners. They are highly qualified researchers in the field of oncology and have made incredible progress. Their experience and knowledge have helped them to establish a highly effective newsletter on oncology. The newsletter grew fast in oncology under the guidance of both these men.

This newsletter is weekly and allows open access to all kinds of readers who want to get informed about the latest technologies in the field of oncology or who want to publish their work in oncology. The newsletter is run by two well-known oncologists has attracted the attention of a wide variety of readers all around the world. This has helped a lot in oncology, from discoveries to new treatments and drugs, now many patients can be saved with greater ease. The death of patients suffering from cancer has greatly reduced with the help of this newsletter and to know more click here


Sheldon Lavin’s Journey from a Financial Consultant to a Leader in the Meat Industry

Sheldon Lavin is well known for his investment in OSI Group, the leader in meat products business. One thing that most people do not know about Mr. Sheldon is that he is a financial adviser by profession. This is arguably brought about by Mr. Lavin’s huge success in the business through his company OSI Group. How then did Sheldon Lavin find himself in an industry he had little experience in?

Sheldon Lavin’s journey to the meat industry dates back to his Chicago banking practice. During his time as a banker, Mr. Lavin was approached by his bank to arrange financing for Otto & Sons as it was referred to then. After arranging this finance, Sheldon was requested by the bank to work for the company as a full time financial adviser, a position he turned down for lack of training in the meat industry. However, Mr. Sheldon would later work with the company as a private consultant gaining knowledge and interest in the industry. At the end of the 1970s, Mr. Sheldon seized an opportunity and joined the company as an equal partner in the business.

Mr. Sheldon’s success in the company is motivated by his vision and appreciation of his employees. The financial advisor turned entrepreneur’s vision for OSI Group was for it to become the number one global food processing company. This, OSI Group has been able to achieve and even surpass thanks to its physical presence in 17 countries and over 70 food process plants. Lavin has been able to make this happen by positively influencing his employees. Despite having rules and bureaucracy to follow, OSI Group operates as a huge family where everybody needs each other. This setup has fueled positive energy within the organization which has helped the company achieve its objectives easily.

To know more visit @:

The Rise and Rise of Amicus Therapeutics

Based in Cranbury, New Jersey, Amicus Amicus Therapeutics Inc. is a global pharmaceutical company specializing in the treatment of rare and orphaned diseases. Amicus Therapeutics was made public in 2007 under the trademark FOLD, after a failed initial public offering in the previous year in 2006. Amicus Therapeutics Inc. majors in the treatment of rare and orphaned diseases, especially Lysosomal Storage Disorders. It has created a reputation for itself over the years for having the broadest portfolio in the pharmaceutical industry.


Amicus Therapeutics boasts a unique set of medicines and technologies which have been effective in treating and providing comfort for people with rare and devastating disorders. Some of the diseases that the company has specialized in treating include Pompe disease, Lysosomal Storage Disorders, and Fabry disease. They have also committed to the treatment of genetically connected skin disorders such as Epidermolysis Bullosa (EB). The company places the treatment of patients with rare and orphaned diseases at the center of their operations which revolve around clinical programs, innovative science, and commercial organization. Their main aim and that which is the primary driving factor for the organizational culture is the need to make a meaningful difference in the lives of their patients and the caregivers assigned to them.


It must be noted that Amicus Therapeutics relies solely on contractors to manufacture its products since it lacks the manufacturing capacities, on account of it being a relatively young company ( After its 2007 IPO, Amicus Therapeutics expanded from its single site in New Jersey to open a research site in San Diego. The company received a half a million US dollar grant from the Michale J Fox Foundation to support its studies in the treatment of rare diseases. It would go on to receive another grant from the Alzheimer’s Drug Discovery Foundation. Both these grants have helped the company grow and enhance its research efforts. They also speak to the confidence that the company has inspired in the medical world. Buoyed by these grants and robust financial growth in recent years, Amicus Therapeutics acquired its competitor Callidus Biopharma in November of 2013. This move gave the company ownership to proprietary and intellectual material pertinent to the treatment of Pompe disease.

More about Amicus Therapeutics on Facebook

Beneful: For The Love of Dogs

Who doesn’t love a talking dog? I can’t think of any better way to sell dog food than to use cute dogs to do it. Apparently, neither can Beneful commercial . All of their commercials sport an adorable mutt spouting off hilarious one liners. If you have ever seen a commercial for Bush’s Baked Beans you know exactly what I am talking about and to know more click here.

What’s almost funnier than the talking canines is the adults who are talking to them. It reminds me of when I say good morning to my sweet little Midnight while cooing and staring at her like she really must understand every word I utter. The adults in this commercial are sure to make any mutt loving adult want to go out and do the right thing, which in this case is, of course to buy Beneful. Why not? Every dog deserves the best.